The tweet was deleted by the author.
But we saved everything 🙂.
Definium Therapeutics announced today that its Emerge study, the first Phase 3 clinical trial for its pharmaceutical LSD in major depressive disorder (MDD), delivered positive topline results.
The company described the outcome as a major advance toward introducing novel psychiatric treatments, signaling increased momentum for psychedelic-based approaches in mental health care.
Earlier this year, Definium Therapeutics joined peers at ASCP in Miami Beach to present AI-powered advances for psychiatric drug development. The company has also investigated how neuroplasticity and psychedelics may disrupt negative mental cycles. These efforts reflect the firm's continued focus on innovative approaches in mental health.